Crinetics Pharmaceuticals shares are trading higher after UBS initiated coverage on the stock with a Buy rating and announced a $55 price ta

Crinetics Pharmaceuticals shares are trading higher after UBS initiated coverage on the stock with a Buy rating and announced a $55 price target.